|1.||Toubanakis, Christos: 4 articles (01/2011 - 05/2005)|
|2.||Nikou, George C: 4 articles (01/2011 - 05/2005)|
|3.||Krenning, Eric P: 4 articles (05/2010 - 04/2003)|
|4.||Pacak, Karel: 3 articles (08/2015 - 09/2002)|
|5.||Sarmiento, Juan M: 3 articles (07/2015 - 01/2003)|
|6.||Menda, Yusuf: 3 articles (08/2014 - 02/2004)|
|7.||Delpassand, Ebrahim S: 3 articles (01/2014 - 06/2008)|
|8.||Carrasquillo, Jorge A: 3 articles (08/2012 - 09/2002)|
|9.||Anthony, Lowell B: 3 articles (06/2012 - 04/2002)|
|10.||Mallas, Elias: 3 articles (01/2011 - 05/2005)|
12/15/1997 - "This study explores the efficacy of OctreoScan and a newly developed handheld gamma detector probe (H-probe2) for the localization of neuroendocrine abdominal tumors. "
10/01/1996 - "The aim of this study was to evaluate the ability of Octreoscan scintigraphy to detect such tumors. "
01/01/1994 - "The results are the following: 2 patients of group A (secreting tumors) had a positive three-step ISG, whereas all the patients but one of the same group had a positive pentetreotide study; all the patients of group B (nonsecreting tumors) had a positive three-step ISG and 4 had a positive pentetreotide scintigraphy. "
07/01/2015 - "The sensitivity of Octreoscan versus PET varied similarly when analyzed by WHO tumor grade: Grade 1 (79 vs. 52 %; p = 0.16), Grade 2 (85 vs. 86 %; p = not significant), and Grade 3 (57 vs. 100 %; p = 0.02). "
09/01/2014 - "111 In-pentetreotide SPECT CT Value in Follow-up of Patients with Neuro-Endocrine Tumors."
|2.||Neoplasm Metastasis (Metastasis)
07/01/2005 - "OCTREOSCAN revealed a solitary lesion in the right hepatic lobe, not detected by all the previous studies, while it detected, as a whole, the primary lesion in 10/11 (91%), and the metastases in 3/4 (75%) pts. In 7/11 (63.6%) the primary lesion was located in the pancreas, whereas in the rest it was in the duodenum or retroperitoneum. "
05/01/2010 - "Octreoscan and whole body CT scan confirmed a locally advanced disease, in the absence of metastases. "
01/01/2010 - "An octreoscan prior to surgical procedures revealed multiple osseous and intra-hepatic metastases. "
01/01/2008 - "OctreoScan showed avid uptake in 77.8% of patients with hepatic metastases. "
01/01/2008 - "As in our case, new scintigraphic methods, such as 111-In-pentetreotide scintigraphy (Octreoscan), may occasionally reveal 123-I-metaiodobenzylguanidine-negative distant metastases and help to establish an early diagnosis of malignancy. "
|3.||Carcinoid Tumor (Carcinoid)
01/01/1999 - "We conclude that: 1. the octreoscan scintigraphy in the follow-up of resected carcinoids can give false-positive results and 2. in consequence, the mediastinoscopy is a discriminating investigation in case of mediastinal lymph nodes disease."
02/01/2013 - "The scintigraphic investigation of neuroendocrine tumours such as carcinoids has depended on standard techniques such as I-metaiodobenzylguanidine and In-pentetreotide imaging. "
10/01/2010 - "The bronchial biopsy confirmed that it was a typical bronchial carcinoid and the octreoscan showed a single focus of high uptake coinciding with this lesion. "
09/01/2008 - "This case illustrates that hardware SPECT/CT fusion imaging utilizing indium-111 pentetreotide to evaluate metastatic carcinoid tumors can be useful. "
06/01/2007 - "Follow-up of a carcinoid tumor in the middle ear by in-111 pentetreotide scintigraphy."
05/01/2004 - "The authors present two cases of gastrin-producing carcinoma demonstrated by scintigraphy with In-111 pentetreotide. "
04/01/2005 - "Our preliminary results seem to demonstrate the efficacy of octreotide as adjuvant therapy in large cell neuroendocrine carcinomas of the lung when results of preoperative indium In-111 pentetreotide scintigraphy were positive. "
09/01/1997 - "The authors present the cases of two patients who underwent somatostatin receptor scintigraphy (SSRS) using In-111 pentetreotide: one for the study of suspected paraneoplastic ACTH hypersecretion, and the other for a restaging of breast carcinoma with neuroendocrine features. "
05/01/1997 - "111In-pentetreotide is unlikely to replace 123I-MIBG as a first-line routine diagnostic scintigraphic modality; compared to pentetreotide or MIBG, (V)DMSA seems to be highly sensitive only in medullary thyroid carcinomas."
03/01/2011 - "Two thymomas were at stage I, 1 thymoma and 1 thymic carcinoma at stage II, 1 insular carcinoma of presumably thymic origin at stage IV, and 1 thymic carcinoid at stage IV. OctreoScan consistently accumulated in primary and/or metastatic sites of thymic tumors while no radiotracer uptake was detected in the 2 patients with benign thymic hyperplasia. "
|5.||Neuroendocrine Tumors (Neuroendocrine Tumor)
06/01/2008 - "Safety and efficacy of radionuclide therapy with high-activity In-111 pentetreotide in patients with progressive neuroendocrine tumors."
01/01/2012 - "To study the long term benefits, toxicity and survival rate in patients with neuroendocrine tumors receiving multiple cycles of high activity In-111 Pentetreotide therapy. "
12/01/2001 - "The study describes the results of Octreoscan SPET (OCTSPET) qualitative and semi-quantitative evaluation in 38 patients with suspected pancreatic neuroendocrine tumors. "
07/01/2015 - "Clinicians may order Octreoscan or positron emission tomography (PET) scan for staging patients with neuroendocrine tumors (NETs). "
07/01/2015 - "Octreoscan Versus FDG-PET for Neuroendocrine Tumor Staging: A Biological Approach."
|2.||Somatostatin Receptors (Somatostatin Receptor)
|3.||Somatostatin (Somatotropin Release-Inhibiting Factor)
|6.||Adrenocorticotropic Hormone (ACTH)
|9.||Growth Hormone (Somatotropin)
|10.||Guanidine (Guanidine Nitrate)
|1.||Drug Therapy (Chemotherapy)